News

Zacks Investment Research on MSN2d
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...
Regeneron CRL for Eylea extension not surprising, says Oppenheimer
Oppenheimer keeps an Outperform rating on Regeneron (REGN) with a $925 price target after the FDA denied the company’s attempt to extend the ...
Fierce Pharma3d
FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD
The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...
Regeneron Pharmaceuticals, Inc.: Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...
Ophthalmology Times6d
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...
Ophthalmology Times7d
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...
Drug Store News8d
Biocon Biologics secures market entry date for Eylea biosimilar
Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...
Regeneron: Still A Biotech Juggernaut
Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...
Biocon share price jumps 4% as subsidiary secures market entry for Yesafili in US
Biocon share price has gained 1.6% in one month, but the stock has declined 11% on a year-to-date (YTD) basis. Biocon shares have rallied 23% in one year and more than 46% in two years.
PipelineReview.com9d
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...
Biocon Biologics Ltd.: Biocon Biologics Secures Market Entry Date for Yesafili, an Interchangeable Biosimilar to Eylea, in the U.S.
BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...